Company Overview
Snapshot
Founded in June 2021, Revium Rx operates with 1–10 employees. The company completed the acquisition of LipoVation Ltd. in February 2025, a strategic move to enhance its nanoparticle drug development capabilities.
Business overview
Revium Rx develops advanced delivery systems for various indications, focusing on hard-to-treat diseases by enhancing and improving encapsulated therapeutics. The company's pipeline includes antibiotics for antimicrobial-resistant bacteria, an immune checkpoint inhibitor adjuvant for solid tumors, and a novel immunization platform. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, Revium Rx serves the global market with its B2B business model.
Strategic signal
Revium Rx's acquisition of LipoVation Ltd. in February 2025 signals a significant strategic expansion in its nanoparticle drug development capabilities. This move is poised to accelerate the company's efforts in tackling critical health challenges like antibiotic resistance and cancer, demonstrating a clear intent to strengthen its position in advanced drug delivery systems and broaden its therapeutic horizons.
Log in to access full profile ›Q&A
- What are Revium Rx's main competitive advantages in the Health Tech & Life Sciences market? ›
- How has the company's funding evolved over time? ›
- Which customers or partners use Revium Rx's technology? ›
- What is Revium Rx's intellectual property portfolio? ›
- Who are the key competitors in the Health Tech & Life Sciences space? ›